Status:
COMPLETED
Effects of Oligo-fucoidan on Leiomyoma Patients
Lead Sponsor:
Taipei Medical University
Collaborating Sponsors:
Hi-Q Marine Biotech International, Ltd.
Conditions:
Uterine Leiomyoma
Eligibility:
FEMALE
20-55 years
Phase:
EARLY_PHASE1
Brief Summary
Uterine leiomyoma is the most common benign tumor in women, with an incidence rate of approximately 20% among women of reproductive age. Patients may experience severe abdominal pain, abnormal bleedin...
Eligibility Criteria
Inclusion
- Women with uterine fibroids aged 20-55 years.
- Confirmation of uterine fibroids by ultrasound (more than 3 cm, less than 10 cm).
- There are no plans for pregnancy in the past six months.
- There were no plans for uterine fibroid surgery for nearly six months.
- Agree to abide by the research regulations.
Exclusion
- A patient with heart disease, liver disease, kidney disease or any mental illness.
- Patients who are unable to communicate or criticize.
- Pregnant women.
- Patients taking regular medications, including serotonin, antidepressants or other antipsychotics.
- Non-native speakers.
Key Trial Info
Start Date :
August 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06959966
Start Date
August 14 2019
End Date
January 31 2023
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Medical Univeersity
Taipei, Xinyi, Taiwan, 110